Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: Twizlre who wrote (841)	4/22/1998 3:12:00 AM
From: Stephen How	Read Replies (1) \| Respond to of 1432

The Hespan&reg package insert gives some insight into the effects of hetastarch on coagulation. Note the maximum recommended dosage in the insert (20mL/kg/day), and the direct effect of hetastarch on reducing Factor VIII and platelets, and increasing PT and PTT. I reviewed the Hextend&reg Phase III trial results, and saw the same tell-tale effects of hetastarch on coagulation: for both treatment groups, PT and PTT were up (postop vs. preop) and hemocrit and platelet count were down. (see siliconinvestor.com The Hespan&reg package insert is available at btim.dyn.ml.org I also received the Pentaspan&reg insert from Dupont Pharma, and will copy it in later. There seemed to be no maximum recommended dosage for Pentaspan&reg as there is for Hespan&reg this is consistent with studies finding better coagulation properties of the medium weight HES (avg. 280 kD) than hetastarch (avg. 450-480 kD). Steve